Holen Sie sich die Stockscreener-App
11.95
0.75%
-0.09
Handel nachbörslich:
11.98
0.03
+0.25%
Schlusskurs vom Vortag:
$12.04
Offen:
$12.21
24-Stunden-Volumen:
20,868
Relative Volume:
0.63
Marktkapitalisierung:
$157.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.89M
KGV:
-17.07
EPS:
-0.7
Netto-Cashflow:
$-6.48M
1W Leistung:
-3.47%
1M Leistung:
-1.73%
6M Leistung:
-19.26%
1J Leistung:
-9.19%
1-Tages-Spanne:
$11.95
$12.42
1-Wochen-Bereich:
$11.87
$12.95
52-Wochen-Spanne:
$10.52
$21.44
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Firmenname
Greenwich Lifesciences Inc
Sektor
Branche
Telefon
203-434-3290
Adresse
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Vergleichen Sie GLSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
11.95 | 157.08M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-01 | Eingeleitet | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Aktie (GLSI) Neueste Nachrichten
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Large Increase in Short Interest - MarketBeat
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 5.1% in January - MarketBeat
Research Analysts Set Expectations for GLSI FY2024 Earnings - MarketBeat
Learn to Evaluate (GLSI) using the Charts - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for Greenwich LifeSciences (NASDAQ:GLSI) - MarketBeat
What is HC Wainwright’s Estimate for GLSI FY2024 Earnings? - Defense World
Greenwich LifeSciences reports progress in FLAMINGO-01 trial - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Given “Buy” Rating at HC Wainwright - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) - PR Newswire
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress in FLAMINGO-01 trial By Investing.com - Investing.com UK
Clinical Trial Success: Greenwich's Breast Cancer Immunotherapy Achieves Critical Patient Milestone - StockTitan
Greenwich LifeSciences: Long Time To Results, Little Cash, Hard To Recommend (GLSI) - Seeking Alpha
(GLSI) Technical Pivots with Risk Controls - Stock Traders Daily
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial - Yahoo Finance
Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial - Marketscreener.com
Greenwich LifeSciences stock gains on approval to add additional sites to Flamingo-01 in Europe - MSN
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe - GlobeNewswire
Major Breakthrough: Cancer Prevention Trial Goes Europe-Wide as Top Medical Centers Join Forces - StockTitan
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland - GlobeNewswire
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across Poland - StockTitan
How to Take Advantage of moves in (GLSI) - Stock Traders Daily
Greenwich LifeSciences gains after GP2 commercial manufacturing update - MSN
Barclays PLC Has $123,000 Stake in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Bullish Greenwich LifeSciences Insiders Loaded Up On US$3.39m Of Stock - Yahoo Finance
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01 - GlobeNewswire
Harvard, Johns Hopkins Join Greenwich LifeSciences' Phase III Breast Cancer Vaccine Trial - StockTitan
Greenwich LifeSciences stock gains on GP2 update (GLSI) - Seeking Alpha
Greenwich LifeSciences Provides Update on Commercial Manufacturing - GlobeNewswire
Greenwich LifeSciences Achieves Major Manufacturing Milestone for Breast Cancer Immunotherapy GP2 - StockTitan
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI) - Marketscreener.com
Long Term Trading Analysis for (GLSI) - Stock Traders Daily
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01 - GlobeNewswire
Greenwich LifeSciences expands trial sites in Germany - Investing.com India
Greenwich Lifesciences Announces Partnership with GBG in Germany for Flamingo-01 - Marketscreener.com
Greenwich LifeSciences CEO acquires $31,275 in common stock By Investing.com - Investing.com Australia
Greenwich LifeSciences CEO acquires $31,275 in common stock - Investing.com India
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 2,500 Shares - MarketBeat
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus.com
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France - The Manila Times
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across France with Unicancer Network - StockTitan
Geode Capital Management LLC Raises Stock Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Barclays PLC Increases Position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Greenwich Lifesciences CEO Snehal Patel buys $39,391 in stock By Investing.com - Investing.com Australia
Finanzdaten der Greenwich Lifesciences Inc-Aktie (GLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):